Zidesamtinib

Zidesamtinib · Nuvalent Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Zidesamtinib, covering 2026-02-17 to 2026-02-17. Get the full timeline:

Most recent: Clinical Trial Update: Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

See pricing